Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II trial of AT-307 for the treatment of CASQ2-related catecholaminergic polymorphic ventricular tachycardia

Trial Profile

A phase I/II trial of AT-307 for the treatment of CASQ2-related catecholaminergic polymorphic ventricular tachycardia

Planning
Phase of Trial: Phase I/II

Latest Information Update: 16 May 2018

At a glance

  • Drugs AT-307 (Primary)
  • Indications Ventricular tachycardia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 May 2018 New trial record
    • 09 May 2018 According to an Audentes Therapeutics media release, IND has been submitted for AT-307. The FDA has completed review and provided a short list of questions to be addressed prior to the IND becoming active. The company expects to submit responses in the coming weeks.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top